Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.

MLA

Ryu, Won-Ji, et al. “Destabilization of β-Catenin and RAS by Targeting the Wnt/β-Catenin Pathway as a Potential Treatment for Triple-Negative Breast Cancer.” Experimental & Molecular Medicine, vol. 52, no. 5, May 2020, pp. 832–42. EBSCOhost, https://doi.org/10.1038/s12276-020-0440-y.

APA

Ryu, W.-J., Lee, J. D., Park, J.-C., Cha, P.-H., Cho, Y.-H., Kim, J. Y., Sohn, J. H., Paik, S., & Choi, K.-Y. (2020). Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer. Experimental & Molecular Medicine, 52(5), 832–842. https://doi.org/10.1038/s12276-020-0440-y

Chicago

Ryu, Won-Ji, Jeong Dong Lee, Jong-Chan Park, Pu-Hyeon Cha, Yong-Hee Cho, Jee Ye Kim, Joo Hyuk Sohn, Soonmyung Paik, and Kang-Yell Choi. 2020. “Destabilization of β-Catenin and RAS by Targeting the Wnt/β-Catenin Pathway as a Potential Treatment for Triple-Negative Breast Cancer.” Experimental & Molecular Medicine 52 (5): 832–42. doi:10.1038/s12276-020-0440-y.